Clinical Trial

Invasive Candidiasis in Critical Care

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 5, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The combination of acute phase marker monitoring and the "T2Candida" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-12.
Trial Details
NCT Number NCT06456151
Lead Sponsor University Hospital Ostrava
Collaborators: University Hospital, Motol
Conditions Invasive Candidiasis
Enrollment 100 participants
Start Date 2024-04-11
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-05